According to our drug sensitivity analyses, ATP6V1G2 is associated with nelarabine, a type of drug targeting T-cell antigens (Salvaris and Fedele, 2021), methylprednisolone, which can improve the opsoclonus myoclonus syndrome associated with NB (Zhu et al., 2021), and sapacitabine, a nucleoside analogue inducing DNA strand breaks (Liu et al., 2012), which has been reported to play a role in the treatment of advanced solid (Denlinger et al., 2021) tumor. This evidence concerns the gene ATP6V1G2 and neuroblastoma.